These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22890)

  • 1. Does dopamine play a role in schizophrenia?
    Carlsson A
    Psychol Med; 1977 Nov; 7(4):583-97. PubMed ID: 22890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic drugs, neurotransmitters, and schizophrenia.
    Carlsson A
    Am J Psychiatry; 1978 Feb; 135(2):165-73. PubMed ID: 23684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in biogenic amine synthesis and turnover induced by hypoxia and/or foot shock stress. II. The central nervous system.
    Brown RM; Snider SR; Carlsson A
    J Neural Transm; 1974; 35(4):293-305. PubMed ID: 4548084
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
    Nissbrandt H; Engberg G; Pileblad E
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Deakin JF; Longden A
    Lancet; 1976 Sep; 2(7985):563-6. PubMed ID: 60635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional role and pharmacological regulation of the dopaminergic system of the brain].
    Raevskiĭ KS
    Vestn Ross Akad Med Nauk; 1998; (8):19-24. PubMed ID: 9771125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism.
    Kehr W
    Eur J Pharmacol; 1984 Jan; 97(1-2):111-9. PubMed ID: 6421606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dopamine hypothesis of schizophrenia: a review.
    Meltzer HY; Stahl SM
    Schizophr Bull; 1976; 2(1):19-76. PubMed ID: 779020
    [No Abstract]   [Full Text] [Related]  

  • 9. Increase of striatal dopamine turnover by drugs: interference with granular storage or receptor blackade?
    Saner A; Pletscher A
    Eur J Pharmacol; 1977 Mar; 42(2):155-60. PubMed ID: 844496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthyroidism: specifically increased response to central NA-(alpha-)receptor stimulation and generally increased monoamine turnover in brain.
    Strömbom U; Svensson TH; Jackson DM; Engström G
    J Neural Transm; 1977; 41(1):73-92. PubMed ID: 915501
    [No Abstract]   [Full Text] [Related]  

  • 11. Central catecholamine neurons, behavior and neuroleptic drugs: an analysis to understand the involvement of catecholamines in schizophrenia.
    Fuxe K; Nyström M; Tovi M; Smith R; Ogren SO
    J Psychiatr Res; 1974; 11():151-61. PubMed ID: 4156786
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of effect of prolactin on the dopaminergic receptor sensitivity in striatal and limbic areas after experimentally-induced alterations in its peripheral levels.
    Cebeira M; Hernandez ML; Rodriguez de Fonseca F; de Miguel R; Fernandez-Ruiz JJ; Ramos JA
    Life Sci; 1991; 48(6):531-41. PubMed ID: 1671524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of GABAergic drugs on dopamine catabolism in the nigrostriatal and mesolimbic dopaminergic pathways of the rat.
    Gundlach AL; Beart PM
    J Pharm Pharmacol; 1981 Jan; 33(1):41-3. PubMed ID: 6114152
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat.
    Ahlenius S; Hillegaart V; Wijkström A
    Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):551-6. PubMed ID: 2570361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of chronic neuroleptic administration on cerebral dopamine receptor function.
    Rupniak MN; Jenner P; Marsden CD
    Life Sci; 1983 May; 32(20):2289-311. PubMed ID: 6133203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
    Cools AR; van Rossum JM
    Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Neuroscience; 1978; 3(9):773-83. PubMed ID: 30919
    [No Abstract]   [Full Text] [Related]  

  • 19. Adenylate cyclase from various dopaminergic areas of the brain and the action of loxapine.
    Clement-Cormier YC
    Adv Exp Med Biol; 1977; 90():183-90. PubMed ID: 930743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central actions of dopa and dopamine.
    Sourkes TL
    Rev Can Biol; 1972; 31():Suppl:153-68. PubMed ID: 4403289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.